[The efficacy of immunomodulating preparations in treating patients with chronic cholestatic liver diseases].
Radchenko. V G VG; Mitrofanova. T I TI; Serebriakova. V I VI; Vinogradova. G L GL
Key Findings
- Thymalin increased total lymphocytes and T‑cell counts
- It improved the functional activity of immune cells and lowered immunoglobulin and immune‑complex levels
- These immune changes were linked to better clinical signs of chronic cholestatic liver disease
Practical Outcomes
- The results show thymalin may help patients with specific liver conditions, but there’s no clear guidance for healthy individuals or dosage for anti‑aging use. More research is needed before biohackers can safely incorporate it into general health protocols.
Summary
In a study of 102 people with chronic liver disease, the peptide thymalin (used with activin) and the drug levamisole boosted immune cells and reduced harmful immune proteins, helping to calm liver inflammation.
Abstract
A study of 102 patients with chronic cholestatic liver diseases revealed that levamisole, T + activin and thymalin possess an immunostimulating effect increasing the level of lymphocytes, T-lymphocytes, activate the functional activity of lymphocytes in patients with chronic cholestatic hepatitis and primary biliary cirrhosis. T = activin, thymalin produce a more pronounced normalization of the immune response by increasing the contents of T-lymphocytes and their subpopulations, elevating the functional activity of mononuclears, reducing the concentration of immunoglobulins, cyclic immune complexes. These changes favour controlling the immuno-inflammatory process in the liver, normalization of clinical manifestation of the disease.
Study Information
pubmed
1992